Search Results

Salubris Biotherapeutics, Inc. today announced a new capital infusion of $35 million to fund continued research and development of clinical and pre-clinical programs.

Salubris Biotherapeutics, Inc. announced it received $35 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced that positive initial data from the first-in-human study evaluating JK08 in adults with solid tumors were presented in a poster session during the European Society of Medical Oncology Annual Congress 2023.

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive updated results from the completed Phase 1b study of JK07 in patients with HFrEF.

Salubris Biotherapeutics, Inc., a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, announced positive updated results from the ongoing Phase 1b study of JK07 in heart failure with reduced ejection fraction.

Salubris Biotherapeutics, Inc. today announced it received $32 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.

Salubris Biotherapeutics, Inc. today reported new data from Cohort 2 of the ongoing Phase 1 study evaluating JK07, the Company’s lead drug candidate, for the treatment of heart failure with reduced ejection fraction (HFrEF).